DDInter1789 DDInter1676
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Thalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Thalidomide {u} (Compound) treats {v} (Disease) hematologic cancer
Thalidomide {u} (Compound) binds {v} (Gene) FGFR2
Thalidomide {u} (Compound) upregulates {v} (Gene) TGFBR2
Thalidomide {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Immunologically Active Molecule Activity
Thalidomide {u} (Compound) downregulates {v} (Gene) ARNT2
Thalidomide {u} (Compound) causes {v} (Side Effect) Myocardial ischaemia
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Astemizole
Thalidomide {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Thalidomide (Compound) resembles Lenalidomide (Compound)
Thalidomide (Compound) treats hematologic cancer (Disease)
Thalidomide (Compound) binds FGFR2 (Gene)
Thalidomide (Compound) upregulates TGFBR2 (Gene)
Thalidomide (Compound) is included by Decreased Immunologically Active Molecule Activity (Pharmacologic Class)
Thalidomide (Compound) downregulates ARNT2 (Gene)
Thalidomide (Compound) causes Myocardial ischaemia (Side Effect)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Astemizole
Thalidomide may lead to a major life threatening interaction when taken with Rotavirus vaccine